Todd Foley
CIK 1473930 · last filed 2026-01-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$220.31M
Companies
11
Total Filings
67
Lifetime Open-Market Net
-$124.13M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKTS | Director | 4,002,533 | $24.21 | $96.90M | $4.19M | 1 | 2026-01-14 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 2,268,195 | $2.65 | $6.01M | -$17.12M | 17 | 2023-06-12 |
| TRDA | Director | 4,425,784 | $6.08 | $26.91M | $2.00M | 3 | 2022-06-06 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 3,041,865 | $10.15 | $30.87M | -$61.38M | 4 | 2021-11-24 |
| CHIASMA, INC (CHMA) Delisted | Director | 10,426 | $3.76 | $39.2K | $0 | 7 | 2021-08-05 |
| RYTM | Director | 909,258 | $106.13 | $96.50M | -$48.86M | 26 | 2021-03-16 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | 10%+ Owner | 389,842 | $23.01 | $8.97M | -$21.85M | 1 | 2021-02-04 |
| Oncorus, Inc. (ONCR) Delisted | 10%+ Owner | 2,675,677 | $0.12 | $322.6K | $18.25M | 1 | 2020-10-08 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | 10%+ Owner | 3,351,048 | — | — | -$250.2K | 2 | 2014-03-11 |
| Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Director | 62,920 | — | — | $892.9K | 1 | 2014-02-06 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Director | — | — | — | $0 | 1 | 2010-01-20 |
Recent Filings · Page 2 of 7
67 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-05 | CHIASMA, INC (CHMA) Delisted | Disp (D) | — | $0 | EDGAR |
| 2021-07-13 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −27,351 | -$917.7K | EDGAR |
| 2021-06-30 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −8,460 | -$288.1K | EDGAR |
| 2021-06-28 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −12,640 | -$423.6K | EDGAR |
| 2021-06-23 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −18,859 | -$648.0K | EDGAR |
| 2021-06-21 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −18,294 | -$617.8K | EDGAR |
| 2021-06-16 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −2,743 | -$91.2K | EDGAR |
| 2021-06-10 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −27,067 | -$921.5K | EDGAR |
| 2021-06-07 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −25,622 | -$820.3K | EDGAR |
| 2021-06-02 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −16,786 | -$545.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.